This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (36)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Bullous Diseases  • Diagnosis  • Prognosis/ Outcomes  • Pemphigoid  • Immunologic Disorders  • Alert me on articles by topic

The Latest in Diagnosis, Prognosis, and Therapy

Neil J. Korman, PhD, MD

Arch Dermatol. 1998;134:1137-1141.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

When I was a dermatology resident in the mid-1980s, I became fascinated, some might say obsessed, with autoimmune blistering diseases. At that time, interest in and advances in the understanding of these diseases were on the rise. Since then, enormous leaps in our understanding of the pathophysiological features of these autoimmune blistering diseases have been made in large part because of the widespread application of sophisticated molecular biological techniques to ascertain the target antigens against which autoimmune responses are directed. Our appreciation of the full spectrum of bullous pemphigoid (BP), the most common of all the autoimmune blistering diseases, has grown as a function of advances in not only the basic science arena but also the clinical arena. In this editorial I focus my comments on key points relevant to caring for patients with BP, with the understanding that many of these clinical advances have . . . [Full Text of this Article]

DIAGNOSIS

PROGNOSIS

TREATMENT

CONCLUSIONS

From the Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio.

RELATED ARTICLE

Evaluation of Clinical Criteria for Diagnosis of Bullous Pemphigoid
Loïc Vaillant, Philippe Bernard, Pascal Joly, Catherine Prost, Bruno Labeille, Christophe Bedane, Brigitte Arbeille, Elisabeth Thomine, Philippe Bertrand, Catherine Lok, Jean-Claude Roujeau, and for the French Bullous Study Group
Arch Dermatol. 1998;134(9):1075-1080.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Retrospective Analysis of Patients With Bullous Pemphigoid Treated With Methotrexate
Kjellman et al.
Arch Dermatol 2008;144:612-616.
ABSTRACT | FULL TEXT  

A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid
Beissert et al.
Arch Dermatol 2007;143:1536-1542.
ABSTRACT | FULL TEXT  

Treatment of Bullous Pemphigoid by Low-Dose Methotrexate Associated With Short-term Potent Topical Steroids: An Open Prospective Study of 18 Cases
Dereure et al.
Arch Dermatol 2002;138:1255-1256.
FULL TEXT  

Oral and Topical Corticosteroids in Bullous Pemphigoid
Korman et al.
NEJM 2002;347:143-145.
FULL TEXT  

Risk Factors for Lethal Outcome in Patients With Bullous Pemphigoid: Low Serum Albumin Level, High Dosage of Glucocorticosteroids, and Old Age
Rzany et al.
Arch Dermatol 2002;138:903-908.
ABSTRACT | FULL TEXT  

A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid
Joly et al.
NEJM 2002;346:321-327.
ABSTRACT | FULL TEXT